Published Date: 13 Mar 2023
MCh Plastic and Reconstructive Surgery or Chirurgiae Master in Plastic and Reconstructive Surgery also known as MCh in Plastic and Reconstructive Surgery.
Read Full NewsPsychotropics are associated with increased BMI, and users with a high BMI genetic risk score and an unhealthy lifestyle have triple the risk for CVD, new research shows.
Tafasitamab and lenalidomide are likely to be approved with R-CHOP for frontline DLBCL, but with bispecific antibodies on the horizon, the role of the combination is uncertain.
In a phase 3 trial of patients with dedifferentiated liposarcoma, the CDK4/6 inhibitor extended progression-free survival more than sixfold.
A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
A phase 3 trial evaluates the safety and efficacy of an investigational bispecific antibody with chemotherapy compared to standard treatment in advanced squamous NSCLC.
In an interim analysis of a randomized phase 2 trial, asandeutertinib improved intracranial response and intracranial PFS vs osimertinib in patients with EGFR-mutated NSCLC with brain metastases.
1.
Financial hardship common in patients with cancer
2.
A small rise in cancer was observed following the 1986 Chernobyl accident.
3.
Launch of the hereditary cancer clinic for precision oncology at Kokilaben Hospital.
4.
A new drug delivery system may help patients with a rare eye cancer
5.
Research team uncovers the underpinnings of head and neck cancers
1.
AI in Genomics: Decoding the Human Genome for Cancer Treatment
2.
Transforming Cancer Care: Metrics, Informatics, Equity, and Real-World Evidence
3.
Thyroid Cancer and Insulin Resistance: Unraveling the Complex Interplay for Better Patient Outcomes
4.
Elevating Hematology Oncology: Modern Approaches for Smarter Diagnosis and Treatment
5.
Revolutionizing Cancer Treatment with Trilaciclib: How a New Drug is Transforming Outcomes
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma
2.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion- Part II
3.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I
4.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
5.
Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation